Group 1 - Tianchen Medical's stock price increased by 3.6%, reaching 60.11 CNY per share, marking a new high [2] - The company's total market capitalization surpassed 4.878 billion CNY [2] - The trading volume amounted to 84.4529 million CNY [2]

Group 1 - The stock price of Tianchen Medical (688013) closed at 55.89 yuan on September 9, 2025, down by 1.91% with a turnover rate of 2.01% and a trading volume of 16,300 shares, resulting in a transaction amount of 91.7574 million yuan [1] - On September 9, the net inflow of main funds was 926,600 yuan, accounting for 1.01% of the total transaction amount, while retail funds had a net outflow of 38,700 yuan, representing 0.04% of the total transaction amount [1][3] - Tianchen Medical will participate in the 2025 semi-annual performance briefing for the medical device industry on September 17, 2025, where the company will address investor inquiries regarding its semi-annual operational results and financial status [1][3]

Core Viewpoint - Tianchen Medical announced its plan to participate in the 2025 semi-annual performance briefing for the medical device and equipment industry on September 17, 2025 [2] Company Summary - Tianchen Medical will attend the performance briefing, indicating its engagement with the industry and potential for future growth [2] Industry Summary - The event is part of a collective performance briefing for the medical device and equipment sector, highlighting the industry's focus on transparency and performance metrics [2]

证券代码：688013 证券简称：天臣医疗 公告编号：2025-053 会议召开方式：上证路演中心图文及网络文字互动 投资者可于 2025 年 09 月 10 日（星期三）至 09 月 16 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 tsbs@touchstone.hk）将需要了解和关注的问题提前提供给公司。公司将在说明 会上对投资者普遍关注的问题进行回答。 天臣国际医疗科技股份有限公司（以下简称"公司"或"天臣医疗"）于 2025 年 8 月 27 日在上海证券交易所网站（www.sse.com.cn）披露了《天臣医疗 2025 年半年度报告》，为便于广大投资者更全面深入地了解公司 2025 年半年度经营 成果、财务状况、发展理念，公司计划于 2025 年 09 月 17 日（星期三）15:00- 17:00 参加由上海证券交易所举办的 2025 年半年度科创板医疗器械及医疗设备 行业集体业绩说明会，就投资者关心的问题进行交流。 天臣国际医疗科技股份有限公司 关于召开 2025 年半年度科创板医疗器械及医疗设备 行业集体业绩说明会的公告 本公司董事会及全体董事保 ...

Company Overview - Tianchen Medical is located in Suzhou Industrial Park, Jiangsu Province, and was established on August 18, 2003. The company was listed on September 28, 2020. Its main business involves the research, innovation, production, and sales of high-end surgical staplers [1]. - The company operates in the pharmaceutical and biological industry, specifically in the medical devices and medical consumables sector. It is associated with concepts such as high dividends, buybacks, strong annual performance, margin financing, and specialized innovation [1]. Financial Performance - As of June 30, Tianchen Medical reported a revenue of 156 million yuan, representing a year-on-year growth of 17.66%. The net profit attributable to the parent company was 48.21 million yuan, showing a year-on-year increase of 67.10% [1]. - Since its A-share listing, Tianchen Medical has distributed a total of 171 million yuan in dividends, with 139 million yuan distributed over the past three years [2]. Stock Performance - On September 8, Tianchen Medical's stock price decreased by 2.15%, trading at 55.88 yuan per share, with a total transaction volume of 35.89 million yuan and a turnover rate of 0.78%. The company's total market capitalization is 4.535 billion yuan [1]. - Year-to-date, the stock price has increased by 236.02%. Over the last five trading days, it has decreased by 3.36%, while it has increased by 49.89% over the last 20 days and 104.91% over the last 60 days [1]. - As of the latest data, the number of shareholders is 4,148, a decrease of 6.64% from the previous period, while the average circulating shares per person increased by 7.11% to 19,564 shares [1]. Capital Flow - In terms of capital flow, there was a net outflow of 913,500 yuan from main funds, with large orders buying 3.92 million yuan (10.94% of total) and selling 4.84 million yuan (13.48% of total) [1].

Summary of Key Points Core Viewpoint - Tianchen Medical (688013) reported a closing price of 57.11 yuan on September 5, 2025, with a 3.93% increase and a trading volume of 23,700 shares, amounting to a total transaction value of 133 million yuan [1]. Trading Information - On September 5, the net outflow of main funds was 21.61 million yuan, accounting for 16.28% of the total transaction value [1][3]. - Retail investors had a net inflow of 24.49 million yuan, representing 18.44% of the total transaction value [1]. Company Announcements - Tianchen Medical plans to reappoint Gongzheng Tianye Accounting Firm as the auditing institution for the year 2025, which has 349 registered accountants and 81 listed company audit clients [1]. - The company intends to distribute a cash dividend of 5.00 yuan (including tax) for every 10 shares, totaling 40.33 million yuan, which represents 83.66% of the half-year net profit attributable to shareholders [1][3].

Core Viewpoint - Tianchen Medical (688013) has shown significant growth in revenue and net profit for the first half of 2025, driven by strategic advancements in minimally invasive and intelligent medical technologies [1][5]. Group 1: Financial Performance - For the first half of 2025, the company achieved operating revenue of 156 million yuan, representing a year-on-year increase of 17.66% [1]. - The net profit attributable to shareholders reached 48 million yuan, marking a substantial year-on-year growth of 67.10% [1][5]. - The company plans to distribute a cash dividend of 5.00 yuan per 10 shares (including tax), totaling approximately 40.33 million yuan, which accounts for 83.66% of the net profit attributable to shareholders [4][5]. Group 2: Strategic Development - The company's strategy focuses on dual engines of development: minimally invasive capabilities driven by end-effector components and the intelligent ecosystem of surgical robots supported by the M platform [1]. - The MA project is centered on 5mm ultra-minimally invasive technology, aiming for compact design, cost optimization, ease of operation, data security, and platform openness, currently in the research and validation phase [1][2]. Group 3: Research and Development - The R&D expenses for the first half of 2025 amounted to approximately 18.9 million yuan, reflecting a year-on-year increase of 21.34%, which constitutes 12.10% of the revenue [3][5]. - The company has made significant progress in patent applications, with 11 new applications and 53 new authorizations, including 44 invention patents, bringing the total to 822 patents, of which 565 are invention patents, accounting for 69% [3]. Group 4: Market Position and Stock Performance - As of September 5, 2025, Tianchen Medical's stock closed at 57.11 yuan, up 2.16% from the previous week, with a market capitalization of 4.635 billion yuan, ranking 80th in the medical device sector [1]. - The stock reached a nearly one-year high of 59.97 yuan on September 3, 2025, with a weekly low of 54.05 yuan [1].

Summary of Key Points Core Viewpoint - Tianchen Medical (688013) reported a closing price of 54.95 yuan on September 4, 2025, reflecting a decline of 3.87% with a turnover rate of 3.59% and a trading volume of 29,100 shares, resulting in a transaction value of 164 million yuan [1]. Trading Information Summary - On September 4, the net outflow of main funds was 21.41 million yuan, accounting for 13.09% of the total transaction value [1][3]. - The net outflow of retail funds was 574,000 yuan, representing 0.35% of the total transaction value [1]. - Retail investors saw a net inflow of 21.99 million yuan, which constituted 13.44% of the total transaction value [1]. Company Announcement Summary - Tianchen Medical plans to reappoint Gongzheng Tianye Accounting Firm (Special General Partnership) as the auditing institution for the year 2025. The firm, established in 1982, has qualifications for securities and futures-related businesses, with 349 registered accountants and 81 listed company audit clients as of the end of 2024 [1]. - The company intends to distribute a cash dividend of 5.00 yuan (including tax) for every 10 shares, based on a total share capital of 80,663,539 shares after deducting repurchased shares. The total cash dividend amounts to 40,331,769.50 yuan (including tax), which represents 83.66% of the semi-annual net profit attributable to the parent company [1][3]. - No capital reserve conversion to share capital or stock dividends will be conducted. The above proposal has been submitted for review at the third extraordinary general meeting of shareholders in 2025 [1].

Core Points - The company is holding its third extraordinary general meeting of shareholders in 2025 to ensure the rights of all shareholders and maintain order during the meeting [1][2] - The meeting will include a combination of on-site and online voting, with specific time frames for each voting method [6] - The agenda includes the reappointment of the auditing firm and the proposal for the 2025 semi-annual profit distribution plan [11][10] Meeting Procedures - Shareholders and their representatives must sign in at least half an hour before the meeting and present required documentation [2] - The meeting will follow a structured agenda, allowing shareholders to express their opinions and vote on proposals [3][4] - The meeting will be witnessed by a legal representative from a law firm, who will provide a legal opinion [6][10] Auditing Firm Information - The proposed auditing firm is Gongzheng Tianye Certified Public Accountants, established in 1982, with a significant number of registered accountants and a strong track record in auditing [6][7] - The firm reported a total audited revenue of 308.57 million yuan for 2024, with 265.46 million yuan from auditing services [7][8] - The company plans to negotiate the audit fees for 2025 based on business scale and complexity [9][10] Profit Distribution Proposal - As of June 30, 2025, the company has a distributable profit of approximately 93.96 million yuan, with a net profit of about 48.21 million yuan for the first half of 2025 [11][12] - The proposed cash dividend is 5.00 yuan per 10 shares, amounting to a total distribution of approximately 40.33 million yuan, which is 42.92% of the available distributable profit [11][12] - The proposal does not include capital reserve transfers or stock dividends [12][13]

证券代码：688013 证券简称：天臣医疗 | 2025 | | 年第三次临时股东会会议须知 3 | | --- | --- | --- | | 2025 | | 年第三次临时股东会会议议程 2 | | 2025 | | 年第三次临时股东会会议议案 3 | | | 议案 1: | 关于公司续聘 年度审计机构的议案 2025 3 | | | 议案 2: | 关于公司《2025 年半年度利润分配方案》的议案 6 | 2 天臣国际医疗科技股份有限公司 2025 年第三次临时股东会会议资料 天臣国际医疗科技股份有限公司 天臣国际医疗科技股份有限公司 2025 年第三次临时股东会 会议资料 2025 年 9 月 天臣国际医疗科技股份有限公司 2025 年第三次临时股东会会议资料 目录 2025 年第三次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会 议的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委 员会《上市公司股东会规则》以及《天臣国际医疗科技股份有限公司章程》（以 下简称"《公司章程 ...